ARTICLE | Clinical News
Neovacs planning Phase III for lupus therapy on mixed Phase IIb data
July 3, 2018 3:05 PM UTC
Neovacs S.A. (Euronext:ALNEV) plans to start Phase III testing of lupus candidate IFNalpha-Kinoid despite reporting mixed data from a Phase IIb trial in the indication on Tuesday. IFNalpha-Kinoid is an immunotherapy against interferon (IFN) alpha.
The therapy met one of the study's two primary endpoints. IFNalpha-Kinoid failed to significantly improve British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response rate at week 36 vs. placebo, but did significantly reduce the expression of IFN-induced genes at week 36 vs. placebo (p<0.0001)...
BCIQ Company Profiles
BCIQ Target Profiles